-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Oramed Pharmaceuticals Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2022 to Q2 2024.
- Oramed Pharmaceuticals Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $14.2M, a 474% increase year-over-year.
- Oramed Pharmaceuticals Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $38.1M.
- Oramed Pharmaceuticals Inc. annual Nonoperating Income (Expense) for 2023 was $22.9M, a 680% increase from 2022.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)